8-K: Harrow Acquires Melt Pharma for Non-Opioid Sedation

Harrow, Inc. has entered into a definitive merger agreement to acquire the remaining equity interests in Melt Pharmaceuticals, Inc., expanding its portfolio with a non-opioid procedural sedation therapy.

Summary

• Harrow, Inc. entered into an Agreement and Plan of Merger on September 24, 2025, to acquire the remaining equity interests in Melt Pharmaceuticals, Inc.
• As of June 30, 2025, Harrow already owned approximately 45% of Melt's outstanding equity and held a mid-single digit royalty on future net sales of Melt's primary product, MELT-300.
• The acquisition involves an initial cash payment of approximately $4.3 million at closing.
• Contingent consideration includes an aggregate cash payment of approximately $87.2 million upon U.S. Food and Drug Administration (FDA) approval of the MELT-300 product candidate.
• Further contingent consideration includes the issuance of approximately 1,112,000 shares of Harrow's common stock upon receipt of pass-through status and a J-Code for MELT-300 from the Center for Medicare & Medicaid Services.
• Additional contingent cash payments, totaling up to approximately $261.0 million, are tied to the achievement of various annual net sales milestones ranging from $100.0 million to $1.0 billion per year.
• All regulatory and commercial milestones must be achieved on or before December 31, 2035.
• The transaction was negotiated and approved by a special committee of Harrow's Board of Directors, comprised of independent directors, due to existing ownership interests and relationships of Harrow's management with Melt.
• Melt's lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of midazolam (3mg) and ketamine (50mg), designed for rapid, predictable non-opioid, non-IV sedation and analgesia.
• In November 2024, Melt announced positive topline results from its pivotal LOUISE Phase 3 Study, demonstrating MELT-300's statistical superiority to sublingual midazolam alone (P=0.009) and placebo (P=<0.0001) for successful procedural sedation.
• The LOUISE Phase 3 Study was conducted under a Special Protocol Assessment (SPA) agreement with the FDA, confirming the study design's adequacy for a future regulatory submission.
• A recently completed cardiac safety study indicated that MELT-300 did not alter normal heart rhythm, supporting its safety profile.

Sentiment

Score: 8

Explanation: The acquisition is strategically significant, expanding Harrow's market reach into a multi-billion-dollar segment with a promising non-opioid product. Positive Phase 3 results and existing market familiarity for the delivery method are strong positives. The contingent payment structure mitigates some risk, aligning payments with successful milestones. However, future FDA approval and commercial success are not guaranteed, and the total potential cost is substantial.

Positives

• Acquisition of MELT-300, a clinical-stage, non-opioid, non-IV therapy for procedural sedation, addresses a critical public health need by reducing reliance on opioids.
• Positive topline results from the pivotal LOUISE Phase 3 Study for MELT-300 demonstrated statistical superiority in providing successful procedural sedation.
• The Phase 3 study was conducted under a Special Protocol Assessment (SPA) agreement with the FDA, confirming the study design would adequately support a future regulatory submission.
• MELT-300's safety profile is supported by a recently completed cardiac safety study, which indicated no alteration of normal heart rhythm.
• The acquisition offers immediately accretive launch potential due to Harrow's existing market familiarity with its compounded MKO Melt, used in over 500,000 cataract surgeries by over 700 U.S. ophthalmologists.
• Entry into the multi-billion-dollar U.S. procedural sedation market with potential label expansion opportunities into tens of millions of other procedures annually beyond ophthalmology (e.g., MRIs, colonoscopies, dental, gastroenterology).
• Strengthens Harrow's perioperative portfolio of surgical solutions and diversifies its business outside its core U.S. ophthalmic operations.
• Operational synergies are expected from leveraging Harrow's existing commercial and regulatory infrastructure to accelerate Melt's market introduction.
• Improved patient experience is anticipated with MELT-300's less invasive, needle-free, non-opioid, under-the-tongue delivery using Catalent's ZYDIS oral dissolving tablet technology.
• Expanded accessibility for physicians to perform procedures comfortably in office and outpatient settings, reducing reliance on operating rooms.
• Global application potential for MELT-300, with patents issued in North America, Australia, Europe, Asia, and the Middle East.

Risks

• Changes in market conditions could impact the commercial success of MELT-300.
• Risks associated with the negotiation of final transaction documents, despite the Merger Agreement being signed.
• Potential changes in operations, business, financial, or other conditions relevant to the planned transactions.
• Execution risks related to the completion of the transactions described, including obtaining Melt stockholder approval.
• General risks detailed in Harrow's Annual Report on Form 10-K for the year ended December 31, 2024, and its other filings with the SEC.
• Inability to complete the potential transactions on expected terms or at all if any risks or uncertainties materialize, or if underlying assumptions are incorrect.
• Risks related to liquidity or results of operations.
• Challenges in successfully implementing Harrow's business plan, developing and commercializing products, identifying and acquiring additional products, managing pharmacy operations, servicing debt, and obtaining necessary financing.
• Difficulties in recruiting and retaining qualified personnel, managing any growth, and successfully realizing the benefits of previous and future acquisitions and collaborative arrangements.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks, including litigation matters, and other uncertainties related to pharmacy and pharmaceutical business.
• Uncertainty regarding physician interest in and market acceptance of current and any future formulations and compounding pharmacies generally.

Future Outlook

Harrow plans to submit a New Drug Application (NDA) for MELT-300 to the FDA in 2027, with a potential U.S. commercial launch in 2028. Upon FDA approval, Harrow intends to ensure customer access to an FDA-approved product and discontinue its compounded MKO Melt. The company also plans to identify suitable development and commercialization partners to make MELT-300 available outside the U.S. market.

Management Comments

• "We are excited to welcome Melt Pharmaceuticals back into the Harrow family. This acquisition represents another important step in our mission to deliver innovative, patient-focused ophthalmic disease management solutions that go beyond the limitations of traditional care." Mark L. Baum, Chief Executive Officer of Harrow.
• "MELT-300 has the potential to redefine the standard of care for millions of patients by providing a convenient, non-opioid alternative for procedural sedation. By reducing reliance on opioids, MELT-300 not only addresses a critical public health need but also opens the door to significant market expansion opportunities across a wide range of medical procedures." Mark L. Baum, Chief Executive Officer of Harrow.
• "Sedation hasn't changed much over the past few decades. Having demonstrated the clinical superiority of the MELT-300 drug candidate over its individual components, including midazolam, we believe the standards of care for sedation will change when the MELT-300 drug candidate is FDA-approved." Larry Dillaha, Chief Executive Officer of Melt Pharmaceuticals.
• "By re-joining Harrow, we gain the resources and expertise needed to accelerate our programs and bring MELT-300 closer to the patients and physicians who need it most. Together, we are committed to transforming the state of the art in the massive US and global procedural sedation market." Larry Dillaha, Chief Executive Officer of Melt Pharmaceuticals.

Industry Context

The acquisition positions Harrow to enter the multi-billion-dollar U.S. procedural sedation market with a novel non-opioid, non-IV alternative. This move addresses the growing demand for reduced opioid exposure and aligns with broader healthcare trends favoring safer, less invasive, and more accessible sedation options. MELT-300 has the potential to replace or supplement traditional IV sedation in a wide range of medical interventions, significantly expanding Harrow's market footprint beyond its core ophthalmic business.

Comparison to Industry Standards

• MELT-300 utilizes Catalent's ZYDIS oral dissolving tablet technology, which is incorporated into over 35 FDA-approved products, indicating a well-established and accepted delivery method within the pharmaceutical industry.
• Harrow's existing compounded sublingual sedation product, MKO Melt, has been widely used by over 700 U.S. ophthalmologists in more than 500,000 cataract surgeries over a decade, demonstrating a strong foundation of physician trust and market familiarity with this mode of sedation delivery.
• MELT-300's demonstrated statistical superiority to both sublingual midazolam alone and placebo in its pivotal Phase 3 study suggests a significant advancement over existing components and current standards of care for procedural sedation.

Corporate Governance

Related Party Transactions

• Harrow owned approximately 45% of Melt's outstanding equity as of June 30, 2025.
• Certain officers and directors of Harrow, including Mark L. Baum (Chairman and Chief Executive Officer) and Andrew R. Boll (President and Chief Financial Officer), own additional equity interests in Melt.
• Mark L. Baum, Harrow's Chairman and CEO, serves on the board of directors of Melt.
• Melt Pharmaceuticals, Inc. is a former subsidiary of Harrow, Inc. and was carved out as a separately managed business in 2019.

Stakeholder Impact

• **Shareholders (Harrow)**: Potential for significant growth and diversification into a new multi-billion-dollar market, but also substantial contingent payment obligations and execution risks related to FDA approval and commercial success.
• **Shareholders (Melt)**: Will receive an initial cash payment and contingent cash and equity payments, providing a liquidity event and potential upside based on MELT-300's future success.
• **Patients**: Potential access to a new, potentially safer, non-opioid, non-IV option for procedural sedation, which could improve comfort, reduce anxiety, and simplify care.
• **Physicians**: A new tool (MELT-300) that can simplify care, enable more procedures in office and outpatient settings, and address the growing demand for non-opioid alternatives.
• **Employees (Melt)**: Re-integration into Harrow, potentially gaining access to greater resources and expertise to accelerate their programs.

Next Steps

• Melt has agreed to operate its business in the ordinary course until the earlier of the termination of the Merger Agreement and the effective time of the acquisition.
• Melt has agreed to use reasonable best efforts to obtain approval of the Merger Agreement and the transactions contemplated thereby by the requisite Melt stockholders.
• The closing of the Melt acquisition is subject to certain customary closing conditions, including the approval of the requisite stockholders of Melt.
• Harrow plans to submit a New Drug Application (NDA) to the FDA for MELT-300 in 2027.
• A potential U.S. commercial launch of MELT-300 is anticipated in 2028.
• Upon FDA approval of MELT-300, Harrow intends to ensure customer access to the FDA-approved product and discontinue its compounded MKO Melt.
• Harrow intends to identify suitable development and commercialization partners to make MELT-300 available outside the U.S. market.

Key Dates

Recommendation

The acquisition of Melt Pharmaceuticals and its lead product, MELT-300, represents a highly strategic move for Harrow, positioning the company for significant growth and diversification into the multi-billion-dollar procedural sedation market. MELT-300's positive Phase 3 clinical results, non-opioid and non-IV delivery, and use of proven ZYDIS technology address critical unmet needs and align with evolving healthcare trends. Harrow's existing commercial infrastructure and prior success with MKO Melt provide a strong foundation for a successful launch. While the contingent payments are substantial, they are milestone-driven, aligning the acquisition cost with the product's commercial success. This acquisition significantly enhances Harrow's long-term growth prospects and market position.

Keywords

Harrow, Melt Pharmaceuticals, Acquisition, MELT-300, Procedural Sedation, Non-opioid, FDA Approval, Ophthalmology, Pharmaceuticals, Merger, Clinical Stage, Sublingual, Midazolam, Ketamine, HROW